Gamma-Synuclein serves as a novel prognostic factor of extrahepatic and intrahepatic cholangiocarcinoma via promoting cell migration.

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K10609
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Keio University
• Principal Investigator: Hibi Taizo 慶應義塾大学, 医学部(信濃町), 共同研究員 (10338072)
• Research Collaborator: OJIMA Hidenori ; TAKEMURA Yusuke ; OSHIMA Go ; KITAGO Minoru ; ABE Yuta ; YAGI Hiroshi ; YAMAGISHI Seri ; HORI Shutaro ; KUBOTA Naoto ; SAKAMOTO Michiie ; KITAGAWA Yuko
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 胆管癌 / Synuclein γ

Outline of Final Research Achievements

Methods: One hundred and forty nine cases of extra hepatic cholangiocarcinoma (ECC) and intrahepatic cholangiocarcinoma (ICC) were divided immunohistochemically into SNCG positive and negative groups. Clinicopathological factors and outcomes were compared between the groups. We selected BTC cell lines with SNCG overexpression from 17 BTC cell lines and examined the association between SNCG and cell proliferation or migration.
Results: SNCG expression was observed in 32 (21.4%) cases and correlated with poorer differentiation (P = 0.001) and lymph node metastases (P = 0.001). Multivariate analyses revealed SNCG expression as an independent poor prognostic factor of overall survival (P = 0.008 ) and recurrence-free survival (P = 0.006). In vitro assays demonstrated SNCG silencing suppressed cell migration significantly and a part of cell proliferation.

Free Research Field

肝胆膵外科

Academic Significance and Societal Importance of the Research Achievements

道癌は膵癌と同様に予後不良な癌種であり、神経浸潤の頻度も高いがその浸潤、転移機構とSNCGの関連については知られていない。SNCGは新規抗がん剤のターゲットや抗がん剤抵抗性との関連も報告されており、胆道癌におけるSNCGの機能解析により新規抗がん剤開発や治療成績の向上、新規バイオマーカーとなりうると考えられる。